Eli Lilly Sues Six Companies Over Unlawful Sales of Retatrutide
Eli Lilly takes legal action against six entities over the alleged unauthorized sale of its experimental obesity drug retatrutide.
Eli Lilly and Company has initiated legal action against six different companies over the alleged illegal marketing and sales of retatrutide, an experimental obesity treatment currently in development by the pharmaceutical firm.
The lawsuits target entities allegedly distributing unauthorized compounds marketed as the investigational drug, raising regulatory and safety concerns surrounding unapproved peptide products.
Retatrutide is an investigational triple-hormone receptor agonist currently advancing through clinical trials for weight management and metabolic conditions. Eli Lilly has repeatedly warned consumers and health providers against purchasing unverified versions of its pipeline therapeutics from compounding pharmacies and unauthorized online vendors.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →